1. Inicio
  2. Publicaciones
  3. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Puig N
  • Sarasquete ME
  • Balanzategui A
  • Paiva B
  • García H
  • Fumero S
  • Jiménez C
  • Alcoceba M
  • Chillón MC
  • Sebastián E
  • Marín L
  • Montalbán MA
  • Oriol A
  • Palomera L
  • Vidriales MB
  • Bladé J
  • Lahuerta JJ
  • González M
  • Miguel JF
  • García-Sanz R

Grupos

Abstract

We have analyzed the applicability, sensitivity and prognostic value of allele-specific oligonucleotide real-time quantitative PCR (ASO RQ-PCR) as a method for minimal residual disease (MRD) assessment in patients with multiple myeloma (MM), comparing the results with those of multiparameter flow cytometry (MFC). A total of 170 patients enrolled in three consecutive Spanish trials achieving at least partial response after treatment were included. Lack of clonality detection (n = 31), unsuccessful sequencing (n = 17) and suboptimal ASO performance (n = 51) limited the applicability of PCR to 42% of cases. MRD was finally investigated in 103 patients (including 32 previously studied) with persistent disease identified by PCR and MFC in 54% and 46% of cases, respectively. A significant correlation in MRD quantitation by both the techniques was noted (r = 0.881, P<0.001), being reflective of treatment intensity. Patients with < 10(-4) residual tumor cells showed longer progression-free survival (PFS) compared with the rest (not reached (NR) vs 31 months, P = 0.002), with similar results observed with MFC. Among complete responders (n = 62), PCR discriminated two risk groups with different PFS (49 vs 26 months, P = 0.001) and overall survival (NR vs 60 months, P = 0.008). Thus, although less applicable than MFC, ASO RQ-PCR is a powerful technique to assess treatment efficacy and risk stratification in MM.

Datos de la publicación

ISSN/ISSNe:
0887-6924, 1476-5551

LEUKEMIA  SPRINGERNATURE

Tipo:
Article
Páginas:
391-397
PubMed:
23860448
Factor de Impacto:
4,657 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 130

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • multiple myeloma; multiparameter flow cytometry; ASO RQ-PCR; minimal residual disease

Campos de Estudio

Cita

Compartir